-
Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organization Dedicated to Patients with CancerDaiichi Sankyo2020-11-11 20:09:14Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organization
-
DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER2 Positive Early Breast Cancer at High Risk After Neo-adjuvant TherapyDaiichi Sankyo2023-11-09 21:02:38DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER2 Positive
-
ENHERTU® Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric CancerDaiichi Sankyo2023-11-09 21:02:11ENHERTU® Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric Cancer
-
Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T CellsDaiichi Sankyo2023-11-09 21:01:48Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated
-
ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric CancerDaiichi Sankyo2023-11-09 21:01:36ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer
-
Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC at ESMO 2020Daiichi Sankyo2023-11-09 21:01:17Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with
-
Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal CancerDaiichi Sankyo2020-09-15 15:08:35Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced
-
Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC to be Presented at 2020 ESMO Annual MeetingDaiichi Sankyo2023-11-09 20:59:40Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC to be
-
New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and elderly AF patients on LIXIANA (edoxaban) during routine clinical careDaiichi Sankyo2020-09-01 10:19:50New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and
-
NILEMDO® delivers significant cholesterol lowering in addition to statin therapy which is maintained during 2.5 years of treatmentDaiichi Sankyo2023-11-09 20:59:16NILEMDO® delivers significant cholesterol lowering in addition to statin therapy which is maintained during
